DC、CIK、CD3AK细胞免疫治疗对恶性肿瘤患者凝血功能变化的影响  

Influence of DC,CIK,CD3AK cells immunotherapy on malignant tumor patients coagulation

作　　者：张雨洁[1] 王翔[1] 

机构地区：[1]新疆医科大学第五附属医院放化疗科,新疆乌鲁木齐830011

出　　处：《现代肿瘤医学》2017年第5期804-807,共4页Journal of Modern Oncology

摘　　要：目的:探讨DC、CIK、CD3AK细胞免疫治疗前、后的晚期恶性肿瘤患者凝血功能、D-二聚体及血小板的变化。方法:选择DC、CIK、CD3AK细胞免疫治疗的61例晚期恶性肿瘤患者,在采集细胞前1天内及DC、CIK、CD3AK细胞免疫治疗后的3天内行凝血功能、D-二聚体及血小板的检测。比较DC、CIK、CD3AK细胞免疫治疗前、后的凝血功能、D-二聚体及血小板的差异。结果:DC、CIK、CD3AK细胞免疫治疗后D-二聚体、FDP均较前升高(P<0.05),差异有统计学意义;PT、PT_INR较治疗前有所升高,但差异无统计学意义(P>0.05)。结论:DC、CIK、CD3AK细胞免疫治疗3天内D-二聚体及FDP水平升高,在一定程度上加重晚期肿瘤患者高凝状态或血栓形成的风险。Objective： To explore the changes of coagulation,D-dimer and platelet after DC,CIK,CD3 AK cell immunotherapy in advanced malignant tumor patients. Methods： All 61 cases of advanced malignant tumor patients were treated by DC,CIK,CD3 AK cell immunotherapy,all the patients were tested for coagulation,D-dimer and platelet at one day before collecting cell and at three days after DC,CIK,CD3 AK cell immunotherapy. Results： After DC,CIK,CD3 AK cell immunotherapy,D-dimer and FDP increased（ P〈0. 05）,PT,PT_INR increased but no statisically difference（ P〉0. 05）. Conclusion： DC,CIK,CD3 AK cell immunotherapy can increase the level of D-dimer and FDP,to a certain extent,increase the risk of high blood coagulation state or thrombosis in advanced cancer patients.

关 键 词：肿瘤 DC CIK CD3AK D-二聚体 凝血 

分 类 号：R730.58[医药卫生—肿瘤]